Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.21M
Average 2.00M
ZNTL Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 23.8% from a year ago
Cash & equivalents stood at $31.93M at the end of Q1 FY2026, down 23.8% from a year earlier and down 11.3% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Cash & equivalents amounted to 12.6% of total assets at the end of Q1 FY2026, up 1.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 36M USD
- Year-over-year change
- +6.2%
- 4-year CAGR
- -12.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36M | +6.2% |
| FY2024 | 2024-12-31 | 33.9M | +20.9% |
| FY2023 | 2023-12-31 | 28.04M | -34.9% |
| FY2022 | 2022-12-31 | 43.07M | -28.2% |
| FY2021 | 2021-12-31 | 59.96M | — |
Cash & Equivalents vs competitors
How ZNTL compares with its peers on the latest reported figures
- ZNTL's Mar 2026 cash & equivalents of $31.93M is the 8th highest of the 11 companies compared; the peer median is $50.65M.
- Its year-over-year change of -23.8% is the 5th highest of 11, against a peer median of -30.9%.
- Cash & equivalents amounts to 12.6% of total assets for ZNTL, versus a peer median of 28.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $99.37M | +28.7% | -16.4% | 69.1% | |
| Mar 2026 | $90.42M | +48.5% | +4.6% | 88.5% | |
| Mar 2026 | $79.25M | +397.8% | +91.2% | 82.7% | |
| Mar 2026 | $73.68M | -30.6% | +7.1% | 30.4% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $34.79M | -84.7% | -1.3% | 27.3% |
| Mar 2026 | $32.28M | +56.6% | -30.5% | 18.1% | |
| Mar 2026 | $31.93M | -23.8% | -5.8% | 12.6% | |
| Mar 2026 | $22.19M | -75.9% | +10.5% | 11.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $20.96M | -31.1% | -36.1% | 19.8% |
| Mar 2026 | $5.02M | -67.3% | -46.7% | 2.5% | |
| Peer median (excluding ZNTL) | $50.65M | -30.9% | -8.8% | 28.9% | |
Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59.96M | 43.07M | 28.04M | 33.9M | 36M |
| Short-term Investments | 280.17M | 394.3M | 454.88M | 337.18M | 209.9M |
| Net Receivables | 2.64M | 0 | 0 | 5M | 1.93M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 14.56M | 13.8M | 0 | 5.37M |
| Total Current Assets | 350.77M | 451.93M | 496.72M | 386.07M | 253.19M |
| Property, Plant & Equipment (Net) | 52.84M | 50.08M | 41.74M | 37.23M | 29.04M |
| Goodwill | 3.74M | 3.74M | 3.74M | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 40.12M | 23.84M | 2.68M | 2.63M | 0 |
| Tax Assets | 17.52M | 14.15M | 10.34M | 0 | 0 |
| Other Non-current Assets | 7.04M | 9.72M | 6.82M | 4.42M | 6.74M |
| Total Non-current Assets | 121.26M | 101.52M | 65.31M | 44.27M | 35.78M |
| Total Assets | 472.03M | 553.46M | 562.03M | 430.34M | 288.97M |
| Account Payables | 11.59M | 11.25M | 14.93M | 7.44M | 7.21M |
| Short-term Debt | 1.45M | 0 | 2.62M | 3.07M | 3.87M |
| Tax Payables | 971K | 0 | 281K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 281K | 0 | 0 |
| Other Current Liabilities | 20.68M | 384K | (2.9M) | 29.42M | 15.51M |
| Total Current Liabilities | 43.94M | 56.65M | 69.37M | 52.73M | 36.56M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 19.14M | 15M | 10.34M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 2.62M | 1.78M | 849K | 500K |
| Total Non-current Liabilities | 63.6M | 62.79M | 55.27M | 40.43M | 36.2M |
| Total Liabilities | 107.54M | 119.43M | 124.64M | 93.15M | 72.76M |
| Common Stock | 45K | 59K | 70K | 71K | 69K |
| Retained Earnings | (359.56M) | (596.37M) | (888.56M) | (1.05B) | (1.19B) |
| Accumulated OCI | (125K) | (1.35M) | 2.19M | 558K | 196K |
| Other Stockholders Equity | 0 | 0 | 0 | 1 | 0 |
| Minority Interest | 528K | 221K | 107K | 0 | 0 |
| Total Equity | 364.48M | 434.02M | 437.39M | 337.19M | 216.2M |
| Total Debt | 45.91M | 47.33M | 45.77M | 42.65M | 39.58M |
| Net Debt | (14.05M) | 4.26M | 17.74M | 8.75M | 3.58M |
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.